Devices

Recently a pump user reported a sudden increase in her glucose levels lasting a couple of days. Her blood sugars were elevated to 275-320mg/dL, with no ketones present.  Changing her infusion sets did not help. Nor did rotating to a new injection site or even using a fresh vial of insulin. After reviewing her insulin pump we noticed a symbol on her “home screen” saying that a special feature was running.

In this Exclusive Interview, Tim Dunn talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the work of Abbott on CGM use and how the FreeStyle Libre system is helping a variety of patients with diabetes.

New technologies have the potential to revolutionize diabetes care. But what are the advantages and disadvantages of insulin pumps, vs. daily injections? How widely will they be adopted, by patients with type 2 diabetes as well as type 1? What factors will make a difference for adoption – convenience, accuracy, costs? In November, we asked you to help us examine the future of insulin delivery and find the answers to these questions. Now we’re sharing all the results with you, so that you can see for yourself how your fellow members of the diabetes community plan on using CGMs, now and in the future.

In this week's Homerun Slides, understanding the sensor procedure for the Eversense CGM.

In this week's Homerun Slides, explaining how the Eversense CGM System works.

In this week's Homerun Slides, we begin a review of the new Eversense CGM system.

The Omnipod Dash™ device approved for commercialization and release in the U.S. by mid-2018.

Guest Post by David Kliff, Editor, Diabetic Investor

With each passing day, it’s becoming more apparent that CGM will replace BGM as the standard for glucose measurement. CGM systems are becoming more patient-friendly, i.e. no calibrations, simple insertion, and cheaper too. The data provided by CGM is transformative, leading to improved outcomes. It is no longer a question of if this will happen but when this will happen.

Overview from a presentation at the 2018 American Diabetes Associations 78th Scientific Sessions.

The “artificial pancreas” provides glucose control for non-critically ill patients